|
Neobacimyx-H Rx, 1/8 oz
|
|
NEOBACIMYX Ophthalmic Ointment provide a broad spectrum of activity against
the gram-positive and gram-negative bacteria commonly involved in superficial
infections of the eyelid and conjunctiva.
|
Bulk supply needs? please call us at 1-877-247-4633 or email
| More info...
|
|
NEOBACIMYX®-H 1/8 oz Rx by Schering-Plough
(BACITRACIN-NEOMYCIN-POLYMYXIN-HYDROCORTISONE ACETATE 1%)
Sterile, Veterinary Ophthalmic Ointment
Approved by FDA
DESCRIPTION:
The three antibiotics present in
NEOBACIMYX Ophthalmic Ointment provide a broad spectrum of activity against
the gram-positive and gram-negative bacteria commonly involved in superficial
infections of the eyelid and conjunctiva.
ACTIONS:
The overlapping spectra of these three
antibiotics provide effective bactericidal action against most commonly
occurring gram-positive and gram-negative bacteria associated with infections
of the eyes. The range of bactericidal activity encompasses many bacteria
which are, or have become, resistant to other antibiotics, notably Pseudomonas
and Staphylococcus. In susceptible organisms, resistance rarely develops, even
on repeated or prolonged usage. Hydrocortisone acetate exerts a marked
anti-inflammatory action at the tissue level and effectively suppresses
inflammation in many disorders of the anterior segment of the eye. Local
application to the eye often gives rapid relief of pain and photophobia,
particularly in lesions of the cornea.
The combined anti-inflammatory and antimicrobial activity of
NEOBACIMYX-H Ophthalmic Ointment permits effective management of many
disorders of the anterior segment of the eye in which combined activity is
needed.
INDICATIONS:
It may be used in acute or chronic
conjunctivitis, when caused by organisms susceptible to the antibiotics
contained in this ointment. Laboratory tests should be conducted including in
vitro culturing and susceptibility tests on samples collected prior to
treatment.
CONTRAINDICATION:
Ophthalmic preparations containing
corticosteroids are contraindicated in the treatment of those deep, ulcerative
lesions of the cornea where the inner layer (endothelium) is involved, in
fungal infections and in the presence of viral infections.
WARNINGS:
All topical ophthalmic preparations
containing corticosteroids with or without an antimicrobial agent, are
contraindicated in the initial treatment of corneal ulcers. They should not be
used until the infection is under control and corneal regeneration is well
under way.
Clinical and experimental data have demonstrated that corticosteroids
administered orally or by injection to animals may induce the first stage of
parturition if used during the last trimester of pregnancy and may precipitate
premature parturition followed by dystocia, fetal death, retained placenta,
and metritis.
Additionally, corticosteroids administered to dogs, rabbits, and rodents
during pregnancy have resulted in cleft palate in offspring. Corticosteroids
administered to dogs during pregnancy have also resulted in other congenital
anomalies including deformed forelegs, phocomelia, and anasarca.
PRECAUTIONS:
Sensitivity to this ophthalmic ointment is
rare, however, if reactions occur, discontinue use of the preparation.
The prolonged use of antibiotic containing preparations may result in
overgrowth of non-susceptible organisms including fungi. Appropriate measures
should be taken if this occurs. If infection does not respond to treatment in
2 or 3 days, the diagnosis and therapy should be re-evaluated. Animals under
treatment with this product should be observed for usual signs of
corticosteroid overdose which include polydipsia and occasionally an increase
in weight.
Use of corticosteroids, depending on dose, duration, and specific
steroid, may result in inhibition of endogenous steroid production following
drug withdrawal. In patients presently receiving or recently withdrawn from
systemic corticosteroid treatments, therapy with a rapidly action
corticosteroid should be considered in unusually stressful situations. Care
should be taken not to contaminate the applicator tip during administration of
the preparation.
ADVERSE REACTIONS:
Itching, burning, or inflammation may
occur in animals sensitive to the product. Discontinue use in such cases.
SAP and SGPT (ALT) enzyme elevations, polydipsia, and polyuria have
occurred following parenteral or systemic use of synthetic corticosteroids in
dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs.
Cushing’s syndrome in dogs has been reported in association with
prolonged or repeated steroid therapy.
DOSAGE AND ADMINISTRATION:
Apply a thin film over the cornea three or
four times daily. The area to be treated should be properly cleansed prior to
use. Foreign bodies, crusted exudates and debris should be carefully removed.
Insert the tip of the tube beneath the lower lid and express a small quantity
of the ointment into the conjunctival sac in dogs and cats.
HOW SUPPLIED:
NEOBACIMYX-H Ophthalmic Ointment is
available in 1/8 oz (3.5 g) sterile, tamper-proof tube.
Store at room temperature.
Prescription items are NON-RETURNABLE and NON-REFUNDABLE.
Click for order information
All Prices in US Dollars
|
|
|
|
|